Here are the DEF 14A proxy statements from Collegium Pharmaceutical, Inc. (COLL) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow COLL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full COLL filings page.
Collegium Pharmaceutical is asking shareholders to elect eight directors, approve executive pay on an advisory basis, and ratify Deloitte & Touche as auditor at its fully virtual 2026 annual meeting. Shareholders of record on March 31, 2026, representing 32,406,969 shares, may vote online, by phone, mail or during the webcast.
The proxy highlights record 2025 product revenue of $780.6 million, up 23.6%, driven by Jornay PM net revenue of $148.9 million with 48% year-over-year growth and a pain portfolio generating $631.7 million, up 6%. Operating cash flow reached $329.3 million, year-end cash and marketable securities were $386.7 million, and the company closed a $980 million syndicated credit facility while repaying about $581 million of prior term debt.
Collegium returned $25 million to shareholders via repurchases, reports strong governance with seven of eight independent directors, and emphasizes ESG initiatives, employee development, and culture. The compensation program is positioned as pay-for-performance, with a prior say-on-pay vote receiving approximately 91% support.